A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing
Author:
Publisher
Springer Science and Business Media LLC
Subject
Health Policy,Economics and Econometrics,General Medicine
Link
http://link.springer.com/content/pdf/10.1007/s40258-012-0008-7.pdf
Reference34 articles.
1. Persson U, Svensson J, Pettersson B. A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing. Appl Health Econ Health Policy. 2012;10:217–25.
2. Wettermark B, Godman B, Andersen K, et al. Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe. Pharmacoeconomics. 2008;26:537–50.
3. Godman B, Wettermark B, Hoffman M, Anderson K, Haycox A, et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoecon Outcomes Res. 2009;9:65–83.
4. Hugosson K, Engstrom A. Threshold value for a QALY: correlation with disease severity and decision uncertainty [abstract]. Value Health. 2008;11(3):A49.
5. Anell A, Persson U. Reimbursement and clinical guidelines for pharmaceuticals in Sweden: do health-economic evaluations support decision making? Eur J Health Econ. 2005;50:274–9.
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis;International Journal of Environmental Research and Public Health;2020-11-10
2. Medicines Pricing: Limitations of Existing Policies and New Models;Global Pharmaceutical Policy;2020
3. Assessment of External Price Referencing and Alternative Policies;Medicine Price Surveys, Analyses and Comparisons;2019
4. Stock market behavior of pharmaceutical industry in Iran and macroeconomic factors;Economic Change and Restructuring;2018-02-26
5. Evidence on the cost-effectiveness of lifelong antiretroviral therapy for prevention of mother-to-child transmission of HIV: implications for resource-limited countries in sub-Saharan Africa;Expert Review of Pharmacoeconomics & Outcomes Research;2017-08-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3